These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 29121401

  • 1. MP29-02 reduces nasal hyperreactivity and nasal mediators in patients with house dust mite-allergic rhinitis.
    Kortekaas Krohn I, Callebaut I, Alpizar YA, Steelant B, Van Gerven L, Skov PS, Kasran A, Talavera K, Wouters MM, Ceuppens JL, Seys SF, Hellings PW.
    Allergy; 2018 May; 73(5):1084-1093. PubMed ID: 29121401
    [Abstract] [Full Text] [Related]

  • 2. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray.
    Derendorf H, Munzel U, Petzold U, Maus J, Mascher H, Hermann R, Bousquet J.
    Br J Clin Pharmacol; 2012 Jul; 74(1):125-33. PubMed ID: 22356350
    [Abstract] [Full Text] [Related]

  • 3. Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps.
    Bousquet J, Bachert C, Bernstein J, Canonica GW, Carr W, Dahl R, Demoly P, Devillier P, Hellings P, Fokkens W, Klimek L, Lieberman P, Meltzer E, Price D, Ryan D, Wahn U.
    Expert Opin Pharmacother; 2015 Apr; 16(6):913-28. PubMed ID: 25747125
    [Abstract] [Full Text] [Related]

  • 4. Impaired barrier function in patients with house dust mite-induced allergic rhinitis is accompanied by decreased occludin and zonula occludens-1 expression.
    Steelant B, Farré R, Wawrzyniak P, Belmans J, Dekimpe E, Vanheel H, Van Gerven L, Kortekaas Krohn I, Bullens DMA, Ceuppens JL, Akdis CA, Boeckxstaens G, Seys SF, Hellings PW.
    J Allergy Clin Immunol; 2016 Apr; 137(4):1043-1053.e5. PubMed ID: 26846377
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis.
    Meltzer E, Ratner P, Bachert C, Carr W, Berger W, Canonica GW, Hadley J, Lieberman P, Hampel FC, Mullol J, Munzel U, Price D, Scadding G, Virchow JC, Wahn U, Murray R, Bousquet J.
    Int Arch Allergy Immunol; 2013 Apr; 161(4):369-77. PubMed ID: 23652808
    [Abstract] [Full Text] [Related]

  • 7. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis.
    Carr WW, Ratner P, Munzel U, Murray R, Price D, Canonica GW, Mullol J, Virchow JC, Lieberman P, Meltzer E, Bachert C.
    Allergy Asthma Proc; 2012 Apr; 33(6):450-8. PubMed ID: 23127291
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis.
    Berger WE, Shah S, Lieberman P, Hadley J, Price D, Munzel U, Bhatia S.
    J Allergy Clin Immunol Pract; 2014 Apr; 2(2):179-85. PubMed ID: 24607046
    [Abstract] [Full Text] [Related]

  • 11. Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial.
    Berger W, Sher E, Gawchik S, Fineman S.
    Allergy Asthma Proc; 2018 Mar 01; 39(2):110-116. PubMed ID: 29490769
    [Abstract] [Full Text] [Related]

  • 12. MP29-02: a breakthrough for the treatment of allergic rhinitis.
    Bernstein JA.
    Expert Opin Pharmacother; 2013 Oct 01; 14(15):2101-13. PubMed ID: 23977840
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis.
    Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, Munzel U, Bousquet J.
    J Allergy Clin Immunol; 2012 May 01; 129(5):1282-1289.e10. PubMed ID: 22418065
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study.
    Klimek L, Bachert C, Mösges R, Munzel U, Price D, Virchow JC, Wahn U, Bousquet J.
    Allergy Asthma Proc; 2015 May 01; 36(1):40-7. PubMed ID: 25562555
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Nasal immune gene expression in response to azelastine and fluticasone propionate combination or monotherapy.
    Watts AM, West NP, Smith PK, Zhang P, Cripps AW, Cox AJ.
    Immun Inflamm Dis; 2022 Mar 01; 10(3):e571. PubMed ID: 34813682
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.